Evaluation of transrectal ultrasound-based dosimetry for brachytherapy of prostate cancer: a single-center experience

Changzhao Yang, MD1, Zhongtong Lv, MD1, Lingxiao Chen, MD1, Jie Wang, MD2, Xiheng Hu, MD1, Harripersaud Chand, MD1, Xi Sun, MD1, Guyu Tang, MD1, Congyi Tang, MD1, Huichuan Jiang, MD1, Yuan Li, MD1

1Department of Urology, Xiangya Hospital, Central South University, Changsha City, Hunan Province, P. R. China, 2Department of Radiotherapy, Hunan Cancer Hospital, Changsha City, Hunan Province, P. R. China

Abstract

Purpose: To explore the possibility of intraoperative transrectal ultrasound (TRUS)-based dose verification in transperineal brachytherapy (BT) with iodine-125 (125I) seeds for prostate cancer.

Material and methods: Fifteen patients with prostate cancer were treated using BT with 125I seeds. Post-implant TRUS and computed tomography (CT) images were imported into treatment planning system (TPS) for dosimetry. Dosimetry parameters, including minimum dose received by 90% of the volume (D90), percentage of the volume receiving 100% of prescribed dose (V100), and percentage of the volume receiving 200% of prescribed dose (V200) were calculated based on TRUS and CT images, separately. The D90 value of TRUS-based dosimetry was transformed to its expected value. Comparisons of the dosimetric parameters between post-operative verification and preoperative plans were made by paired t-test. One-way ANOVA model was used to assess the differences in preoperative plans. Agreement were evaluated between the preoperative planning and post-operative actual dose parameters using Bland-Altman analysis.

Results: In total, 825 of 125I seeds were implanted successfully in 15 patients. In TRUS-based dosimetry, 674 seeds (81%) were identified clearly in TRUS-based images, and the expected value of D90 parameter showed no significant differences compared with the preoperative planning and CT post-operation results (p > 0.05). In CT-based dosimetry, 810 seeds (98%) were identified clearly in CT-based images, and there was good consistency of D90, V100, and V200 values (p > 0.05). Post-implant CT-based dosimetry indicated that 125I seed implantation had fulfilled the expected plan.

Conclusions: Intraoperative TRUS can be used for dosimetric verification of BT for prostate cancer.

J Contemp Brachytherapy 2020; 12, 4: 327–334
DOI: https://doi.org/10.5114/jcb.2020.98111

Key words: prostate cancer, brachytherapy, TRUS, CT, dosimetry, iodine-125.

Purpose

Brachytherapy (BT) is a standard treatment for patients with localized prostate cancer. BT monotherapy is regarded as a highly efficacious and convenient treatment option for low- to intermediate-risk prostate cancer. It is safe, minimally invasive, and effective, with few complications, produces low radiation pollution, and offers convenient protection, among other advantages over other treatment options [1,2]. Post-implant evaluation is essential for the quality assurance of permanent radioactive seed implants in BT [3]. The efficacy of BT using radioactive seeds depends on several procedural factors, such as transrectal ultrasound (TRUS) imaging, magnetic resonance imaging (MRI), computed tomography (CT) quality, surgical skill of clinicians, placement of needles at desired positions, seeds’ deposition at planned location, and prevention of seed movement or migration [4]. The biological effect produced by radiotherapy is directly determined by the dose of absorbed radiation by tumor tissue. The actual radiation dose of the tumor and surrounding organs is the most direct and important factor affecting therapeutic effects and complications of BT. Post-implant dosimetry is the gold standard in the assurance of implant quality. Moreover, the implant quality of seeds can be assessed by performing dosimetry with parameters, such as D90, V100, and V200 of whole prostate for analysis [5].

At present, CT-based dosimetry is recommended as it can display the prostate as well as the seeds [6]. However, in CT-based dosimetry, seed implant adjustment cannot be performed unless a second surgery is performed.
In addition, CT-based dosimetry has been found to be insufficient, and the prostate edge is difficult to identify, particularly because of the interference of artifacts produced by implanted seeds. In this case, TRUS-based dosimetry might be an alternative method. There is a small number of reports comparing the consistency between TRUS-based and CT-based dosimetry, and few reports have ever studied intraoperative TRUS-based dosimetry of BT for prostate cancer [7,8,9,10]. The purpose of this study was to investigate the possibility of intraoperative TRUS-based dosimetry of BT for prostate cancer.

Material and methods

Patients’ characteristics

This study was approved by the ethic committee of Xiangya Hospital, and all a written consent was obtained from every patient. All patients underwent an evaluation before BT, including a detailed history, physical examination, pelvic CT or MRI imaging, chest X-ray, abdominal ultrasonography, prostate biopsy, and bone scanning. Eligibility criteria were as follows: clinical tumor stage T1 or T2, Gleason score <8, prostate specific antigen (PSA) <20 ng/ml, and no evidence of gross extracapsular extension, regional node involvement, or metastatic disease. Exclusion criteria included excessively large prostate volume (>60 cm³), history of transurethral prostatectomy, history of pelvic radiotherapy or multiple pelvic surgeries, severe diabetes and other systemic diseases, history of neoadjuvant androgen deprivation therapy, or prominent middle zone of prostate [11]. The preimplant CT or MRI imaging data were used to evaluate the risk of potential interference with needle insertion by the pubic bone.

Preimplant plan

The preimplant plan was carried out 1 week before seed implantation in the treatment planning system (TPS, Prowess Panther Brachy version 5.0) with the patients in the dorsal lithotomy position under TRUS guidance. Transverse images of the prostate from base to apex were scanned with a 5 mm slice thickness, and all collected images were imported into the TPS. Axial and sagittal ultrasound images of the prostate were reconstructed by the TPS. After setting tumor matching peripheral dose (MPD) and analyzing maximum tolerance doses of important tissues and organs around the target area, the proper positioning of iodine-125 (125I) radioactive seeds was designed. The minimal peripheral dose (MPD) was prescribed as 145 Gy (TG43) and was planned to cover 99% or more of the PTV, with a 5-mm margin in all directions except posteriorly, where the margin was restricted to 2 or 3 mm. According to the standards recommended by the American Brachytherapy Society, the MPD was established as 145 Gy, with limitations in perirectal tissue D₃ to <150 Gy and in rectum Dᵥ to <145 Gy [12].

Implant procedure

Cross-sectional images of the prostate were taken by TRUS (HI VISION Avius, Hitachi, Japan) and imported into the TPS. An intraoperative implant plan was produced again instantly before seed implantation. A prescribed dose was planned to cover over 95% of the target volume. Seed implants were carried out under general anesthesia. The needles containing 125I seeds (6711 model, CZB Health, China) with an apparent activity of 0.4 mCi and an air kerma strength of 0.508 U (μGy·m²·h⁻¹) were used, and the seeds were inserted into the prostate transperineally through a template for guidance. The seeds were implanted one-by-one at the target point through the needles using a Mick applicator (Figure 1).

Postimplant dosimetry

The appearance and characteristics of the seeds in intraoperative TRUS images were divided into four categories, according to Jamaluddin et al. (Figure 2A): a) Definitely no seed, b) Likely no seed, c) Likely seed, d) Definitely seed [13]. In dosimetry, post-implant D₉₀
V_{100} and V_{200} values were calculated by analyzing the intraoperative TRUS images imported into the TPS.

The ultrasound images of the prostate from base to apex were scanned again immediately after the procedure on the surgical bed and imported into the TPS to immediately evaluate the dosimetry. In post-implant dosimetry, post-implant axial CT images of the pelvis were completed using a CT scanner (SOMATOM Definition, Siemens, Germany) at 3.0-mm slice thickness and 2.5-mm slice spacing, with the patient in supine position at the post-anesthesia care unit. The CT images were also imported into the TPS to evaluate the dosimetry (Figure 2C).

**Statistical analyses**

Application of SPSS version 18.0 was used for statistical analysis and the data was presented as the means ± standard deviations. \( P < 0.05 \) was considered statistically significant. Comparisons of the dosimetric parameters between post-operative verification and preoperative plans were made using a paired \( t \)-test, and dose parameters included D_{90}, V_{100}, and V_{200}. One-way ANOVA was applied to assess the differences in preoperative plans, and in the TRUS-based and CT-based dosimetry. Data was normally distributed when \( t \)-test and ANOVA was performed in SPSS. An agreement was evaluated between the preoperative planning and post-operative actual dose parameters.
Results

Patient characteristics

Fifteen patients consented to participate in this study. The average age of patients was 66 years (range, 59–81 years). The preimplant ultrasound average prostate volume was 49 cm\(^3\) (range, 29–60 cm\(^3\)). Three patients had low-risk prostate cancer, and 12 patients had intermediate-risk prostate cancer. The characteristics of patients are summarized in Table 1.

Seed implant evaluation

Computed tomography images demonstrated that the \(^{125}\)I seed implant had fulfilled the expected plan. In total 825 of \(^{125}\)I seeds were implanted successfully within all patients. TRUS-based verification showed highly echogenic areas on the ultrasound, which corresponded with “Likely seed” or “Definitely seed” (Figure 2A,C,D). Therefore, 674 seeds were clearly identified and included in the analysis. The identification rate of seeds in the TRUS-based images was approximately 81%. In the CT-based verification, 810 seeds were identified. The identification rate of seeds in the CT images was approximately 98%.

Dosimetry

The \(D_{90}\), \(V_{100}\), and \(V_{200}\) dosimetry parameters from the preimplant plan and post-implant CT-based and TRUS-based verifications for the 15 patients are listed and summarized in Tables 2-4. Post-implant CT-based dosimetry indicated that \(^{125}\)I seed implantation had fulfilled the expected plan (Table 5). The comparison of preimplant planned and post-implant dosimetric parameter \(D_{90}\) of the prostate showed no significant differences between TRUS-based and CT-based dosimetry (\(p > 0.05\)). One-way ANOVA showed no significant differences among the preoperative plans and the TRUS-based and CT-based dosimetries (Table 6). In the CT-based dosimetry, there was good consistency among \(D_{90}\), \(V_{100}\), and \(V_{200}\) (Figure 3A-C). Figure 3D indicates good consistency between the expected value of TRUS-based and actual CT-based dosimetry in \(D_{90}\).

Discussion

Low-dose-rate brachytherapy allows for a higher therapeutic radiation dose to the prostate tumor with a steep dose gradient to surrounding normal tissues, resulting in less damage to surrounding normal tissue, fewer complications, mild pain, accurate curative effects, rapid post-operative recovery, and easy acceptance of patients [2,14]. The therapeutic effects of radioactive seeds are directly dependent on dose distribution in the target area. The accuracy of radioactive seed placement is important for optimal dose delivery to the prostate gland, while sparing organs at risk [15]. A preimplant plan is needed to design expected dose distribution within the target area before implantation. Also, post-implant dosimetry is essential to acquire appropriate number and strength of sources, which are considerably important to ensure clinical efficacy and safety by evaluating curative effects, determining the potential need to replant seeds, and providing scientific data for the analysis of dose-effect relationships. A major factor interrupting the concordance between the intended and actual implant results is seed placement accuracy, which is greatly affected by proper needle insertion. Other factors determine the accuracy of needle placement, such as the therapist’s skills level, imaging, and equipment quality as well as the degree of prostate immobilization and mobility. A study by Prestidge et al. evaluated the timing of CT-based post-implant assessment following permanent transperineal prostate brachytherapy, and showed that scans performed at 30th post-implant day appear to adequately describe the time-averaged dose coverage of the prostate [16]. It is best to conduct dosimetry immediately or 1 month after the procedure. As recommended, the implant quality of BT
can be assessed by performing post-implant CT-based dosimetry [17]. In present study, we used Bland-Altman analysis to show the similarity between pre-implant TRUS plan and post-implant CT, and to prove the accuracy of preimplant plan of TRUS. However, the validity of TRUS-based dosimetry during BT procedure for prostate cancer remains to be evaluated.

In this study, 825 of 1251 seeds were implanted successfully in 15 patients from our center, and 810 seeds (98%) were verified by post-implant CT images. We considered the possibility of inter-seed effect before the study. Safigholi et al. [18] believed that this effect might influence dosimetry planning and validation. However, we found that the effect was not so dramatic in the CT-based dosimetry, because there was a good consistency among D90, V100, and V200. The consistency of D90, V100, and V200 values indicated that the 125I seed implant had fulfilled the expected plans. Meanwhile, TRUS-based seed verification showed that 674 seeds (81%) could be clearly identified in the TRUS images, demonstrating that the unclear visualization of seeds in TRUS remains a major challenge. After the D90 value from the TRUS-based dosimetry was transformed to the expected value, we compared the dosimetric parameters between the post-operative verification and preoperative plans. The expected value of the D90 parameter showed no

| Table 2. Preimplant and post-implant dosimetric parameters in target volume of 15 patients |
| No. | D90 [Gy] | V100 [%] | V200 [%] | Pre (TRUS) | Post-CT | Pre (TRUS) | Post-CT | Pre (TRUS) | Post-CT |
|-----|----------|----------|----------|-----------|---------|-----------|---------|-----------|---------|
| 1   | 146.2    | 120.8    | 143.4    | 98.2      | 85.4    | 94.6      | 54.5    | 40.5      | 54.3    |
| 2   | 145.8    | 115.5    | 140.6    | 96.9      | 81.5    | 95.0      | 54.2    | 41.3      | 53.2    |
| 3   | 147.0    | 119.8    | 151.2    | 95.9      | 83.3    | 94.9      | 55.5    | 41.2      | 55.3    |
| 4   | 146.9    | 122.5    | 153.6    | 98.2      | 86.3    | 94.0      | 53.4    | 40.7      | 54.2    |
| 5   | 147.7    | 123.2    | 146.3    | 95.3      | 89.3    | 93.4      | 55.0    | 40.9      | 54.9    |
| 6   | 148.6    | 126.5    | 144.5    | 95.9      | 81.3    | 92.7      | 53.7    | 39.7      | 55.4    |
| 7   | 145.2    | 117.3    | 154.3    | 95.8      | 85.8    | 92.5      | 55.3    | 41.1      | 55.0    |
| 8   | 149.6    | 120.0    | 145.2    | 98.9      | 83.0    | 97.9      | 54.9    | 41.5      | 52.7    |
| 9   | 148.2    | 116.2    | 140.5    | 96.1      | 83.1    | 94.1      | 53.8    | 40.0      | 52.9    |
| 10  | 145.1    | 124.7    | 150.8    | 95.8      | 85.4    | 94.0      | 54.0    | 40.3      | 53.8    |
| 11  | 146.3    | 129.8    | 156.6    | 99.5      | 87.8    | 96.0      | 54.1    | 40.6      | 56.2    |
| 12  | 149.3    | 126.2    | 153.0    | 96.5      | 85.6    | 95.7      | 54.8    | 40.7      | 55.9    |
| 13  | 148.7    | 117.7    | 142.4    | 96.6      | 83.1    | 93.6      | 54.4    | 41.0      | 54.1    |
| 14  | 147.5    | 123.0    | 145.6    | 95.5      | 88.7    | 94.3      | 54.9    | 41.1      | 55.0    |
| 15  | 148.4    | 120.6    | 152.3    | 96.8      | 87.1    | 96.5      | 54.7    | 41.4      | 53.4    |

Pre – preimplant plan, TRUS – TRUS-based, Post-CT – post-implant CT-based, D90 – dose received by 90% of the prostate volume, V100, V200 – percentage of the prostate receiving 100% and 200% of the prescribed radiation dose.

| Table 3. The D90 dosimetry parameter of TRUS expected value |
| No. | TRUS | Percentage | Expected value |
|-----|------|------------|----------------|
| 1   | 120.8 | 0.83       | 145.5          |
| 2   | 115.5 | 0.81       | 142.5          |
| 3   | 119.8 | 0.79       | 151.7          |
| 4   | 122.5 | 0.82       | 149.3          |
| 5   | 123.2 | 0.84       | 146.7          |
| 6   | 126.5 | 0.83       | 152.4          |
| 7   | 117.3 | 0.78       | 150.5          |
| 8   | 120.0 | 0.82       | 146.3          |
| 9   | 116.2 | 0.79       | 147.1          |
| 10  | 124.7 | 0.83       | 150.2          |
| 11  | 129.8 | 0.85       | 151.4          |
| 12  | 126.2 | 0.84       | 150.3          |
| 13  | 117.7 | 0.80       | 147.1          |
| 14  | 123.0 | 0.81       | 151.8          |
| 15  | 120.6 | 0.83       | 145.3          |

Percentage – percentage of seeds identified, expected value – TRUS/percentage of seeds identified

| Table 4. Summary of preimplant planned dosimetry and post-implant dosimetry |
| D90 [Gy] | V100 [%] | V200 [%] |
|----------|---------|---------|
| Preimplant planned | 147.37 ±1.44 | 96.79 ±1.30 | 54.52 ±0.49 |
| TRUS-based | 123.52 ±5.62 | 85.11 ±2.49 | 40.78 ±0.49 |
| TRUS-based expected value | 150.07 ±4.71 | – | – |
| Postimplant CT-based | 148.02 ±3.33 | 95.86 ±1.66 | 53.40 ±0.83 |
The main goal of the present study was to explore the possibility of utilizing single ultrasound-base dosimetry during the procedure. However, only a majority (81%) of the seeds could be observed by ultrasound due to the limitation of image quality. We could speculate that "majority" or "81%" is sufficient for a single ultrasound-base dosimetry, and the general distribution of seeds could be guaranteed according to the detection of ultrasound. Obviously, a single ultrasound-base dosimetry needs large and multicenter study to confirm its validity. It is possible that seed identification could be improved with various methods, such as addition of sagittal imaging, which could enhance visualization. Moreover, using a 3-dimensional view of the needle tracks and its interpolation capability could enhance seed identification rate. The quality of images is also critical for dosimetric analysis. Therefore, we hypothesized that it is possible that real-time intraoperative seed identification could be more precise with future technological improvements.

It might be that prostate enlargements are not be visible immediately after the surgery.

In clinical practice, TRUS-based dosimetry has some important advantages over CT-based dosimetry. CT-based dosimetry cannot be used to compare the locations of implanted seeds with those from a preimplant plan, because of changes in body position in post-implant CT images. Also, post-implant CT cannot readily allow for adjusting seed implants once they are established. In contrast, intraoperative TRUS-based dosimetry cannot only be carried out in real time but allows seed implant adjustment when real-time dosimetry is found to be insufficient. Moreover, the implant procedure is very safe, as the patient is in a constant position during the procedure, and most notably, the prostate and urethra are well visualized in TRUS images. Additionally, needle placement can be followed in real-time during insertion, which allows the adjustment of subsequent needle positions to compensate for any improper needle placement [19]. Overall, TRUS-based dosimetry is reliable and sufficiently flexible for intraoperative dosimetry evaluation.

There are some limitations of this study. First, the number of patients was small, which limits the statistical significance of the outcomes. Second, this study was a single-center experience, not a prospective multicenter research. Additionally, TRUS-based source identification presents the disadvantage of low sensitivity because of relatively poor tissue contrast resolution, estimated between 51% and 83% [20]. The results show that the poor visualization of seeds in TRUS remains a major challenge. The main goal of the present study was to explore the possibility of utilizing single ultrasound-base dosimetry during the procedure. However, only a majority (81%) of the seeds could be observed by ultrasound due to the limitation of image quality. We could speculate that “majority” or “81%” is sufficient for a single ultrasound-base dosimetry, and the general distribution of seeds could be guaranteed according to the detection of ultrasound. Obviously, a single ultrasound-base dosimetry needs large and multicenter study to confirm its validity. It is possible that seed identification could be improved with various methods, such as addition of sagittal imaging, which could enhance visualization. Moreover, using a 3-dimensional view of the needle tracks and its interpolation capability could enhance seed identification rate. The quality of images is also critical for dosimetric analysis. Therefore, we hypothesized that it is possible that real-time intraoperative seed identification could be more precise with future technological improvements.

### Table 5. Comparison of preimplant planned and post-implant CT-based dosimetric parameter of the prostate

| Group          | \(D_{90}\) (mean ± SE) | \(V_{100}\) (mean ± SE) | \(V_{200}\) (mean ± SE) |
|----------------|-------------------------|--------------------------|--------------------------|
| Preimplant planned | 147.37 ±1.44           | 96.79 ±1.30             | 54.52 ±0.49              |
| Post-procedure CT-based | 148.02 ±5.33           | 95.86 ±1.66             | 53.40 ±0.83              |
| \(T\)-value      | 0.43                     | 1.69                     | 0.52                     |
| \(P\)-value      | 0.67                     | 0.11                     | 0.61                     |

### Table 6. Comparison of preimplant planned and post-implant \(D_{90}\) dosimetric parameter of the prostate

| Group          | \(D_{90}\) (mean ± SE) |
|----------------|-------------------------|
| A Preimplant planned | 147.37 ±1.44 |
| B Post-implant TRUS-based expected value | 150.07 ±4.71 |
| C Post-procedure CT-based | 148.02 ±5.33 |

One-way ANOVA: \(F, p\)

| Group | \(D_{90}\) (mean ± SE) | \(T\)-test: \(f, p\) |
|-------|-------------------------|----------------------|
| A vs. B | \(-0.43, 0.67\)         | A vs. C: -0.43, 0.67 |
| A vs. C | 0.44, 0.66              | B vs. C: -0.43, 0.67 |

We performed CT scans and ultrasound immediately after the procedure, and the TRUS prostate volume showed a minor difference when compared with the preimplant ultrasound volume for each patient. The CT scan-determined volume was slightly greater than the volume determined by the preimplant ultrasound.
Fig. 3. Bland-Altman plot showing the scale from the average of preimplant plan to dosimetry parameters with limits of agreement (LoA) (broken lines). Bland-Altman plot of the difference between preimplant and post-implant of CT-based D90 (A), V100 (B), and V200 (C). Figure D shows good consistency between expected value of TRUS-based and actual CT-based dosimetry in D90.

Conclusions
The present study indicates that a single TRUS-based dosimetry can be used for a post-implant assessment of prostate brachytherapy. Compared with CT-based dosimetry, TRUS-based dosimetry can be conveniently performed in real-time. In addition to CT, TRUS is a valuable dosimetry method in prostate cancer brachytherapy.

Acknowledgments
This work was supported by the following grants: the National Key R&D Program of China (No. 2017YFC0908004), the National Natural Science Foundation of China (No. 81874094), the Hunan Provincial Natural Science Foundation of China (No. 2019JJ40484), the Science and Technology Plan Projects of Changsha City (No. kq1801114), the Project from Health and Family Planning Commission of Hunan Province (No. C20180105), and the Innovation and Entrepreneurship in South Central University project (No. 2017gczd032).

Disclosure
The authors report no conflict of interest.
7. Peinemann F, Grouven U, Hemkens LG et al. Low-dose rate brachytherapy for men with localized prostate cancer. *Cochrane Database Syst Rev* 2011; 7: CD008871.

8. Shiraishi Y, Yorozu A, Ohashi T et al. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 2014; 90: 1069-1075.

9. Rice WS Jr, Prestidge BR, Sarosdy MF. Sector analysis of prostate implants. *Med Phys* 2001; 28: 2561-2567.

10. Ishiyama H, Sekiguchi A, Satoh T et al. Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS. *J Contemp Brachytherapy* 2016; 8: 7-16.

11. Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. *Eur Urol* 2017; 71: 618-629.

12. Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. *Brachytherapy* 2012; 11: 6-19.

13. Jamaluddin MF, Ghosh S, Waine MP et al. Quantifying 125I placement accuracy in prostate brachytherapy using postimplant transrectal ultrasound images. *Brachytherapy* 2017; 16: 306-312.

14. Wang J, Wang J, Liao A et al. The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. *Cancer Biother Radiopharm* 2009; 24: 409-416.

15. Stock RG, Stone NN. Importance of post-implant dosimetry in permanent prostate brachytherapy. *Eur Urol* 2002; 41: 434-439.

16. Prestidge BR, Rice WS, Kiefer EJ et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 1998; 40: 1111-1115.

17. Taussky D, Igidbashian L, Donath D et al. Is intraoperative real-time dosimetry in prostate seed brachytherapy predictive of biochemical outcome? *J Contemp Brachytherapy* 2017; 9: 304-308.

18. Safigholi H, Sardari D, Karimi Jashn M et al. An analytical model to determine interseed attenuation effect in low-dose-rate brachytherapy. *J Appl Clin Med Phys* 2013; 14: 4226.

19. Schmid M, Crook JM, Batchelar D et al. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. *Brachytherapy* 2013; 12: 56-64.

20. Han BH, Wallner K, Merrick G et al. Prostate brachytherapy seed identification on post-implant TRUS images. *Med Phys* 2003; 30: 898-900.